Peptide index

Apex Peptide Index™

LL-37

Endogenous cathelicidin-family peptideIMMUNE & INFLAMMATIONLEVEL 02 · Preclinical research

Overview

LL-37 is a naturally occurring peptide associated with innate immune responses and host–microbe interactions. It has been investigated for antimicrobial activity, inflammatory signaling, and tissue repair, but these research interests do not establish therapeutic benefit.

0/3 selected

Biological background

LL-37 is produced by cells of the epithelial and immune systems. Its biological functions involve responses to microbial exposure and tissue damage, with effects that may vary according to the surrounding inflammatory environment.

Mechanism

Research discussed in the notes concerns direct antimicrobial effects and changes in immune activity. Additional work examines processes involved in tissue repair, although the notes do not identify specific molecular pathways or targets.

  1. 01

    Molecular target

  2. 02

    Cellular signal

  3. 03

    Biological process

Research areas

Antimicrobial ActivityImmune Response RegulationCutaneous Tissue RepairPersistent InflammationAutoimmune Disease Biology

Evidence

LEVEL 02 · Preclinical research

Laboratory or animal research exists. Findings do not transfer reliably to people.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

What the source states

The source guide presents LL-37 as a host-defense peptide with activity involving bacterial, viral, and fungal organisms. It also links the peptide to skin repair and the regulation of inflammatory responses. The guide characterizes tolerability favorably while mentioning local irritation, hypersensitivity, and possible excessive immune activation; the supplied notes do not provide evidence sufficient to verify these characterizations.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

What remains uncertain

The notes do not establish whether experimental antimicrobial or repair-related findings translate into meaningful clinical outcomes. The strength of evidence, context-dependent inflammatory effects, and relevance to autoimmune conditions remain insufficiently specified.

Safety information

Safety data are limited, and the supplied material does not support reliable estimates of adverse-event frequency or overall tolerability. Local irritation, hypersensitivity, and excessive immune activation are concerns raised by the guide rather than well-characterized risks in these notes. This summary is for educational purposes and is not medical advice.

Regulatory context

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

References

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

  • LL-37 antimicrobial peptide immunity
  • LL-37 wound healing and skin regeneration
  • LL-37 chronic inflammation and immune modulation

Editorial record

Editorial status
source reviewed
Last updated
2026-09-14
Last reviewed
2026-09-13
Language
EN

Flagged for editorial review

  • · CAMP terminology may conflate the gene or precursor with the mature peptide
  • · Broad antimicrobial claims lack supporting study details
  • · Favorable tolerability and rare-event claims require verification
  • · Clinical relevance of autoimmune claims is unclear

Disclaimer

APEX PHARMA 360® provides scientific and educational information for informational purposes only. The information presented on this platform is not intended to diagnose, treat, cure or prevent any disease and does not constitute medical advice, medical treatment or a recommendation to use any particular substance or compound. Scientific research and regulatory status can change over time and may differ between jurisdictions. Experimental or research-stage compounds should not be interpreted as approved medicines. Always consult an appropriately qualified healthcare professional for individual medical questions and verify applicable laws and regulatory requirements in your jurisdiction.